AI’s Quiet Revolution is Accelerating Drug Discovery, Education and More
The Fast Company article discusses how AI is quietly revolutionizing industries like drug discovery and education by enabling faster, more efficient solutions that address global challenges, with Dotmatics offering personalized demos of their Luma platform to showcase AI capabilities in scientific research.
In a recent Fast Company feature, the impact of artificial intelligence (AI) on industries such as drug discovery and education is explored. The article highlights how AI is driving a quiet revolution, enabling faster and more efficient solutions across these sectors. The transformative potential of AI is discussed in the context of addressing global challenges and shaping the future of various industries.
For those interested in learning more about AI capabilities in scientific research, Dotmatics offers personalized demonstrations of their Luma platform's AI features.
Related
Scripps News America Tonight
Phil Mounteney, VP of Science and Technology at Dotmatics, explains in Scripps News America Tonight how Dotmatics Luma uses AI to transform scientific research and pharmaceutical drug discovery by accelerating innovation, lowering costs, and shortening time-to-market for modern laboratories.
Gray TV Washington DC: AI helping scientists make drug breakthroughs
The Gray TV Washington DC feature highlights how scientists, including Christian Olsen of Dotmatics, are leveraging AI and machine learning to accelerate drug discovery and expedite bringing new drugs to market.
The Future of AI in Drug Discovery
The Forbes article discusses how AI is revolutionizing drug discovery by accelerating R&D and improving decision-making, highlighting Dotmatics’ role in integrating data and applying AI to scientific workflows, while also connecting these advancements to broader innovations in sustainability and global problem-solving.
Maximize Your Data Impact
The article discusses how R&D leaders can maximize the impact of their data by adopting AI/ML technologies, establishing robust data infrastructures, and leveraging automation and external partnerships, as highlighted by insights from Dotmatics' collaboration with LINUS and their State of Science survey revealing scientists' strategic shifts toward automation and partnerships amid scientific and economic challenges.
Addressing Inefficient R&D Workflows
The blog discusses how legacy, fragmented R&D systems hinder innovation in complex, multi-domain scientific research by creating silos and inefficiencies, and presents Dotmatics’ unifying platform as a comprehensive solution that integrates diverse tools, data, and teams to enable smarter collaboration, governed data use, and AI-driven automation for faster, more rigorous innovation.
Fox News Charlotte: The Use of AI in Drug-making
Fox News Charlotte features Christian Olsen, Vice President of Biologics at Dotmatics, discussing how AI, particularly through the Dotmatics Luma platform, is revolutionizing pharmaceutical drug discovery by reducing costs and accelerating time to market while addressing complex research challenges in laboratories.